Repertoire Immune Medicines Doses First Patient in Groundbreaking Cancer Trial with Novel T Cell Therapy#United_States#Cambridge#T_Cell_Therapy#Repertoire_Immune#RPTR-1-201
Repertoire Immune Medicines Doses First Patient in Groundbreaking Cancer Trial with Novel T Cell Therapy
Repertoire Immune Medicines has announced the dosing of the first participant in a Phase 1/2 trial of RPTR-1-201, its innovative immune therapy aimed at treating advanced solid tumors.
third-news.com
April 23, 2026 at 12:36 PM
Repertoire Immune Medicines Doses First Patient in Groundbreaking Cancer Trial with Novel T Cell Therapy#United_States#Cambridge#T_Cell_Therapy#Repertoire_Immune#RPTR-1-201
Repertoire Immune Medicines Partners with Lilly to Innovate Autoimmune Disease Therapies#USA#Cambridge#Lilly#Autoimmune_Diseases#Repertoire_Immune
Repertoire Immune Medicines Partners with Lilly to Innovate Autoimmune Disease Therapies
Repertoire Immune Medicines has teamed up with Eli Lilly to develop groundbreaking therapies for autoimmune diseases, aiming for effective treatments without general immune suppression.
third-news.com
January 29, 2026 at 11:34 AM
Repertoire Immune Medicines Partners with Lilly to Innovate Autoimmune Disease Therapies#USA#Cambridge#Lilly#Autoimmune_Diseases#Repertoire_Immune
Repertoire Immune Medicines Welcomes Dr. Robert Andtbacka as New Chief Medical Officer#United_States#Cambridge#Repertoire_Immune#Robert_Andtbacka#TCR_Bispecific
Repertoire Immune Medicines Welcomes Dr. Robert Andtbacka as New Chief Medical Officer
Repertoire Immune Medicines appoints Dr. Robert Andtbacka as CMO, enhancing leadership as they advance a promising TCR bispecific therapy into clinical trials.
third-news.com
June 4, 2025 at 12:19 PM
Repertoire Immune Medicines Welcomes Dr. Robert Andtbacka as New Chief Medical Officer#United_States#Cambridge#Repertoire_Immune#Robert_Andtbacka#TCR_Bispecific
Repertoire Immune Medicines and Genentech Form Partnership to Innovate Autoimmune Treatments#USA#Cambridge#T_Cell_Therapy#Repertoire_Immune#Genentech
Repertoire Immune Medicines and Genentech Form Partnership to Innovate Autoimmune Treatments
Repertoire Immune Medicines teams up with Genentech to develop innovative T cell-targeted therapies for autoimmune diseases, utilizing their advanced DECODE™ platform.
third-news.com
April 23, 2025 at 11:14 AM
Repertoire Immune Medicines and Genentech Form Partnership to Innovate Autoimmune Treatments#USA#Cambridge#T_Cell_Therapy#Repertoire_Immune#Genentech